These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24119683)

  • 1. [Prevention of serogroup B meningococcal disease using a four-component vaccine].
    Gil A; Barranco D; Batalla J; Bayas JM; Campins M; Gorrotxategi Gorrotxategi P; Lluch J; Martinón-Torres F; Mellado MJ; Moreno-Pérez D; Uriel B; Vázquez JA
    An Pediatr (Barc); 2014 Apr; 80(4):259.e1-23. PubMed ID: 24119683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential Coverage of the 4CMenB Vaccine against Invasive Serogroup B
    Mulhall RM; Bennett D; Cunney R; Borrow R; Lucidarme J; Findlow J; Jolley KA; Bray J; Maiden MCJ; Moschioni M; Serino L; Stella M; Medini D
    mSphere; 2018 Aug; 3(4):. PubMed ID: 30135218
    [No Abstract]   [Full Text] [Related]  

  • 3. High predicted strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in Poland.
    Waśko I; Hong E; De Paola R; Stella M; Moschioni M; Taha MK; Skoczyńska A
    Vaccine; 2016 Jan; 34(4):510-515. PubMed ID: 26686998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
    Bettinger JA; Scheifele DW; Halperin SA; Vaudry W; Findlow J; Borrow R; Medini D; Tsang R;
    Vaccine; 2013 Dec; 32(1):124-30. PubMed ID: 23588089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine.
    Medini D; Stella M; Wassil J
    Vaccine; 2015 May; 33(23):2629-36. PubMed ID: 25882169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicomponent meningococcal serogroup B vaccine (4CMenB; Bexsero(®)): a review of its use in primary and booster vaccination.
    Carter NJ
    BioDrugs; 2013 Jun; 27(3):263-74. PubMed ID: 23575646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
    Dull PM; McIntosh ED
    Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of co-administered meningococcal serogroup B (4CMenB) vaccine: A literature review.
    Abitbol V; Sohn WY; Horn M; Safadi MAP
    Hum Vaccin Immunother; 2023 Aug; 19(2):2245705. PubMed ID: 37642229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal killing of meningococcal W strains isolated in Argentina by the sera of adolescents and infants immunized with 4-component meningococcal serogroup B vaccine (4CMenB).
    Efron A; Biolchi A; Sorhouet Pereira C; Tomei S; Campos J; De Belder D; Moscoloni MA; Santos M; Vidal G; Nocita F; Vizzotti C; Pizza M
    Hum Vaccin Immunother; 2023 Dec; 19(3):2288389. PubMed ID: 38111094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty.
    Andrews SM; Pollard AJ
    Lancet Infect Dis; 2014 May; 14(5):426-34. PubMed ID: 24679664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS.
    Tozer SJ; Smith HV; Whiley DM; Borrow R; Boccadifuoco G; Medini D; Serruto D; Giuliani MM; Stella M; De Paola R; Muzzi A; Pizza M; Sloots TP; Nissen MD
    Hum Vaccin Immunother; 2021 Sep; 17(9):3230-3238. PubMed ID: 33847225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicted coverage by 4CMenB vaccine against invasive meningococcal disease cases in the Netherlands.
    Freudenburg-de Graaf W; Knol MJ; van der Ende A
    Vaccine; 2020 Nov; 38(49):7850-7857. PubMed ID: 33097311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) for bacterial meningitis prevention.
    Esposito S; Castellazzi L; Bosco A; Musio A; Stoddard J
    Immunotherapy; 2014; 6(4):395-408. PubMed ID: 24815780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combined approach to assess the potential coverage of a multicomponent protein-based vaccine.
    Boccadifuoco G; Brunelli B; Pizza MG; Giuliani MM
    J Prev Med Hyg; 2012 Jun; 53(2):56-60. PubMed ID: 23240161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?
    Martin NG; Snape MD
    Expert Rev Vaccines; 2013 Aug; 12(8):837-58. PubMed ID: 23984957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meningococcal Antigen Typing System (MATS): A Tool to Estimate Global Coverage for 4CMenB, a Multicomponent Meningococcal B Vaccine.
    Boccadifuoco G; Brunelli B; Mori E; Agnusdei M; Gianfaldoni C; Giuliani MM
    Methods Mol Biol; 2019; 1969():205-215. PubMed ID: 30877679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials.
    Vesikari T; Esposito S; Prymula R; Ypma E; Kohl I; Toneatto D; Dull P; Kimura A;
    Lancet; 2013 Mar; 381(9869):825-35. PubMed ID: 23324563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A large portion of meningococcal antigen typing system-negative meningococcal strains from spain is killed by sera from adolescents and infants immunized with 4CMenB.
    Abad R; Biolchi A; Moschioni M; Giuliani MM; Pizza M; Vázquez JA
    Clin Vaccine Immunol; 2015 Apr; 22(4):357-60. PubMed ID: 25630407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [From a pathogen's genome to an effective vaccine: the four-component meningococcal serogroup B vaccine].
    Abad R; Martinón-Torres F; Santolaya ME; Banzhoff A; González-Inchausti C; Graña MG; Vázquez JA
    Rev Esp Quimioter; 2019 Jun; 32(3):208-216. PubMed ID: 31148440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.